Hyperion DeFi (HYPD) Competitors $7.74 -0.34 (-4.21%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HYPD vs. AVTX, VOR, IPHA, CHRS, DERM, BIOA, APLT, BHST, ACTU, and PLXShould you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Avalo Therapeutics (AVTX), Vor Biopharma (VOR), Innate Pharma (IPHA), Coherus Oncology (CHRS), Journey Medical (DERM), BioAge Labs (BIOA), Applied Therapeutics (APLT), BioHarvest Sciences (BHST), Actuate Therapeutics (ACTU), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Hyperion DeFi vs. Its Competitors Avalo Therapeutics Vor Biopharma Innate Pharma Coherus Oncology Journey Medical BioAge Labs Applied Therapeutics BioHarvest Sciences Actuate Therapeutics Protalix BioTherapeutics Avalo Therapeutics (NASDAQ:AVTX) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Which has preferable valuation and earnings, AVTX or HYPD? Avalo Therapeutics has higher revenue and earnings than Hyperion DeFi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$441K523.99-$35.13MN/AN/AHyperion DeFi$60K897.84-$49.82M-$58.40-0.13 Does the media favor AVTX or HYPD? In the previous week, Avalo Therapeutics had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 1 mentions for Avalo Therapeutics and 0 mentions for Hyperion DeFi. Avalo Therapeutics' average media sentiment score of 0.19 beat Hyperion DeFi's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Avalo Therapeutics Neutral Hyperion DeFi Neutral Is AVTX or HYPD more profitable? Avalo Therapeutics has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Avalo Therapeutics' return on equity of -48.48% beat Hyperion DeFi's return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Hyperion DeFi -62,238.41%-876.25%-181.67% Do insiders & institutionals believe in AVTX or HYPD? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, AVTX or HYPD? Avalo Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Do analysts prefer AVTX or HYPD? Avalo Therapeutics presently has a consensus price target of $31.67, suggesting a potential upside of 80.23%. Hyperion DeFi has a consensus price target of $2.00, suggesting a potential downside of 74.16%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Avalo Therapeutics is more favorable than Hyperion DeFi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Hyperion DeFi 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 SummaryAvalo Therapeutics beats Hyperion DeFi on 11 of the 14 factors compared between the two stocks. Get Hyperion DeFi News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPD vs. The Competition Export to ExcelMetricHyperion DeFiBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.87M$219.08M$6.15B$10.77BDividend YieldN/A3.81%5.71%4.83%P/E Ratio-0.133.2429.7228.55Price / Sales897.845,399.10499.21189.70Price / CashN/A13.1936.6160.67Price / Book-0.0190.1012.016.61Net Income-$49.82M-$90.99M$3.32B$276.82M7 Day Performance6.46%0.30%1.54%1.96%1 Month Performance-19.46%3.84%6.10%2.53%1 Year Performance-81.29%555.79%61.10%32.80% Hyperion DeFi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPDHyperion DeFi0.2908 of 5 stars$7.74-4.2%$2.00-74.2%-81.1%$53.87M$60K-0.1340AVTXAvalo Therapeutics2.7987 of 5 stars$17.08+11.3%$31.67+85.4%+58.6%$201.88M$441K0.0040VORVor Biopharma2.6901 of 5 stars$29.43+1.5%$77.83+164.5%N/A$198.76MN/A-0.11140Analyst ForecastInsider TradeIPHAInnate Pharma2.0682 of 5 stars$2.12-1.4%$6.50+206.6%+13.5%$198.20M$21.77M0.00220CHRSCoherus Oncology4.0953 of 5 stars$1.79+8.5%$4.51+152.1%+106.2%$191.77M$266.96M1.15330News CoverageAnalyst ForecastDERMJourney Medical1.4558 of 5 stars$7.23+0.4%$12.17+68.3%+26.1%$189.43M$56.13M-19.0390News CoverageAnalyst ForecastBIOABioAge Labs0.0842 of 5 stars$5.36+3.5%N/AN/A$185.70MN/A0.00N/AAPLTApplied Therapeutics3.5808 of 5 stars$1.47+14.8%$4.13+180.6%-84.7%$184.34M$460K-3.2730BHSTBioHarvest Sciences2.0488 of 5 stars$11.28+2.1%$13.67+21.2%N/A$181.46M$30.19M-16.11N/AAnalyst ForecastShort Interest ↑Gap UpACTUActuate Therapeutics1.3547 of 5 stars$7.39-1.2%$20.33+175.1%-4.1%$173.86MN/A0.0010News CoverageAnalyst ForecastPLXProtalix BioTherapeutics2.1011 of 5 stars$2.14+15.1%$15.00+600.9%+126.5%$170.63M$61.95M-16.46200 Related Companies and Tools Related Companies AVTX Competitors VOR Competitors IPHA Competitors CHRS Competitors DERM Competitors BIOA Competitors APLT Competitors BHST Competitors ACTU Competitors PLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HYPD) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperion DeFi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperion DeFi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HYPD Stock Alerts